<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698022</url>
  </required_header>
  <id_info>
    <org_study_id>C-1073-205</org_study_id>
    <nct_id>NCT00698022</nct_id>
  </id_info>
  <brief_title>A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers</brief_title>
  <official_title>A 4-week, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 28-day, single-center, double-blind, placebo-controlled inpatient study of the
      administration of risperidone alone or in combination with mifepristone in healthy adult male
      volunteers to determine the average change in absolute weight at Day 28 compared to baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 28-day, single-center, double-blind, placebo-controlled inpatient study of the
      administration of risperidone alone or in combination with mifepristone in healthy adult male
      volunteers. The primary study objective is to determine the mean change in absolute weight at
      Day 28 compared to baseline in normal healthy male volunteers treated with risperidone plus
      mifepristone or risperidone alone. The secondary study objectives are to determine the mean
      percent change in baseline body weight; and the proportion of subjects that gain less than 5%
      and less than 7% of their baseline body in the treatment groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Weight (kg) From Baseline to Day 28.</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Change in weight (kg) was compared at Baseline and Day 28 for all subjects in all treatment arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Secondary Study Objectives Are to Determine the Mean Percent Change in Baseline Body Weight; and the Proportion of Subjects That Gain Less Than 5% and Less Than 7% of Their Baseline Body Weight in the Treatment Groups.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Safety Objective is to Evaluate the Safety and Tolerability of Mifepristone in Combination With Risperidone in Healthy Male Volunteers.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Risperidone plus mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>risperidone plus mifepristone daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>risperidone plus mifepristone-matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>risperidone plus mifepristone-matched placebo daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>risperidone matched-placebo plus mifepristone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>risperidone-matched placebo plus mifepristone daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>daily risperidone plus mifepristone for 28 days</description>
    <arm_group_label>Risperidone plus mifepristone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone matched placebo</intervention_name>
    <description>risperidone-matched placebo plus mifepristone daily for 28 days</description>
    <arm_group_label>risperidone matched-placebo plus mifepristone</arm_group_label>
    <other_name>Risperdal</other_name>
    <other_name>Corlux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone-matched placebo</intervention_name>
    <description>daily risperidone-matched placebo plus mifepristone for 28 days</description>
    <arm_group_label>risperidone matched-placebo plus mifepristone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone-matched placebo</intervention_name>
    <description>daily mifepristone-matched placebo for 28 days</description>
    <arm_group_label>risperidone plus mifepristone-matched placebo</arm_group_label>
    <other_name>Corlux</other_name>
    <other_name>Risperdal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥ 18 and ≤ 23 kg/m2

          -  Able to provide written informed consent

          -  Routine clinical laboratory tests either within normal limits or not clinically
             meaningful if outside of normal limits

          -  AST, ALT, Tbili within normal limits at screening

          -  Medical and psychiatric history and physical examination devoid of any significant
             findings that would interfere with participation or interpretation of results in this
             study

          -  Agree to use a barrier method of birth control for 28 days following the last dose of
             study medication

          -  Have maintained a stable weight for at least 6 months prior to Screening

        Exclusion Criteria:

          -  Prior or current history of any psychiatric disorder, including eating disorders such
             as anorexia nervosa, bulimia nervosa, or binge-eating disorder

          -  Positive urine drug screen for any drug of abuse (including amphetamines,
             cannabinoids, barbiturates, cocaine, opiates, benzodiazepines) unless prescribed by a
             physician

          -  Participation in a clinical investigation of any drug, biological or other
             investigational therapy within 30 days prior to dosing

          -  Have a history of an allergic reaction to either mifepristone or risperidone

          -  Any other clinically significant abnormality on screening laboratory tests

          -  QTc Bazzett's ≥ 450 msec

          -  History of or current major medical condition, which in the opinion of the
             Investigator would place the patient at undue risk.

          -  Receiving any prescription or over-the-counter medications that could potentially
             affect appetite or weight

          -  Any history of a movement disorder such as Tardive Dyskinesia, Parkinsonism

          -  Any personal or family history of Neuroleptic Malignant Syndrome
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Coleman Gross, MD</last_name>
    <role>Study Director</role>
    <affiliation>Corcept Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dhirubhai Ambani Life Sciences Centre</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.corcept.com</url>
    <description>Sponsor's Website</description>
  </link>
  <reference>
    <citation>Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav Brain Res. 2006 Aug 10;171(2):225-9. Epub 2006 Jun 19.</citation>
    <PMID>16782211</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2008</study_first_posted>
  <results_first_submitted>November 4, 2010</results_first_submitted>
  <results_first_submitted_qc>May 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2012</results_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy</keyword>
  <keyword>weight gain</keyword>
  <keyword>anti-psychotic</keyword>
  <keyword>risperidone</keyword>
  <keyword>mifepristone</keyword>
  <keyword>mitigation</keyword>
  <keyword>weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mifepristone Plus Risperidone</title>
          <description>mifepristone plus risperidone daily</description>
        </group>
        <group group_id="P2">
          <title>Risperidone Plus Mifepristone-matched Placebo</title>
          <description>risperidone plus mifepristone-matched placebo daily</description>
        </group>
        <group group_id="P3">
          <title>Risperidone-matched Placebo Plus Mifepristone</title>
          <description>risperidone-matched placebo plus mifepristone daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mifepristone Plus Risperidone</title>
          <description>mifepristone plus risperidone daily</description>
        </group>
        <group group_id="B2">
          <title>Risperidone Plus Mifepristone-matched Placebo</title>
          <description>risperidone plus mifepristone-matched placebo daily</description>
        </group>
        <group group_id="B3">
          <title>Risperidone-matched Placebo Plus Mifepristone</title>
          <description>risperidone-matched placebo plus mifepristone daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.6" spread="3.9"/>
                    <measurement group_id="B2" value="25.6" spread="3.6"/>
                    <measurement group_id="B3" value="24.9" spread="4.6"/>
                    <measurement group_id="B4" value="25" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Weight (kg) From Baseline to Day 28.</title>
        <description>Change in weight (kg) was compared at Baseline and Day 28 for all subjects in all treatment arms.</description>
        <time_frame>baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone Plus Risperidone</title>
            <description>mifepristone plus risperidone daily</description>
          </group>
          <group group_id="O2">
            <title>Risperidone Plus Mifepristone-matched Placebo</title>
            <description>risperidone plus mifepristone-matched placebo daily</description>
          </group>
          <group group_id="O3">
            <title>Risperidone-matched Placebo Plus Mifepristone</title>
            <description>risperidone-matched placebo plus mifepristone daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight (kg) From Baseline to Day 28.</title>
          <description>Change in weight (kg) was compared at Baseline and Day 28 for all subjects in all treatment arms.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.32"/>
                    <measurement group_id="O2" value="4.23" spread="0.33"/>
                    <measurement group_id="O3" value="2.87" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Secondary Study Objectives Are to Determine the Mean Percent Change in Baseline Body Weight; and the Proportion of Subjects That Gain Less Than 5% and Less Than 7% of Their Baseline Body Weight in the Treatment Groups.</title>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Safety Objective is to Evaluate the Safety and Tolerability of Mifepristone in Combination With Risperidone in Healthy Male Volunteers.</title>
        <time_frame>28 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mifepristone Plus Risperidone</title>
          <description>mifepristone plus risperidone daily</description>
        </group>
        <group group_id="E2">
          <title>Risperidone Plus Mifepristone-matched Placebo</title>
          <description>risperidone plus mifepristone-matched placebo daily</description>
        </group>
        <group group_id="E3">
          <title>Risperidone-matched Placebo Plus Mifepristone</title>
          <description>risperidone-matched placebo plus mifepristone daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>suspected snake bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Roe, MD</name_or_title>
      <organization>Corcept_Therapeutics</organization>
      <phone>650-688-8812</phone>
      <email>rroe@corcept.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

